Merck Serono
The Ethicals business unit from Merck S.A.Merck Serono is the new identity of the Ethicals Business Unit, after the acquisition of the company Serono by the Merck Group.
In the ranking of medical prescription, Merck is the number one laboratory in the field of oral anti-diabetics. Currently, around 8 million patients in over 100 countries benefit form the Merck anti-diabetics families for the treatment of type 2 diabetes.
Moreover, it counts with therapeutic solutions for cardiovascular problems, anti-hypertensives and treatments for cardiac insufficiency. The portfolio also includes thyroid conditions, diarrhea, pain and iron deficiency.
With Serono, Merck S.A. becomes one of the world leaders in biotechnology, women’s health and infertility treatment.
